Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Arch Therapeutics, Inc. (ARTH : OTCBB)
 
 • Company Description   
Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company's lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts.

Number of Employees: 10

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.08 Daily Weekly Monthly
20 Day Moving Average: 146,748 shares
Shares Outstanding: 237.07 (millions)
Market Capitalization: $18.97 (millions)
Beta: -0.51
52 Week High: $0.14
52 Week Low: $0.06
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.11% -1.88%
12 Week -26.94% -21.04%
Year To Date -15.79% -0.26%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
235 WALNUT STREET SUITE 6
-
FRAMINGHAM,MA 01702
USA
ph: 617-431-2313
fax: -
investors@archtherapeutics.com http://www.archtherapeutics.com
 
 • General Corporate Information   
Officers
Terrence W. Norchi - Chief Executive Officer; President and Chairman of
Michael S. Abrams - Chief Financial Officer
Daniel M. Yrigoyen - Vice President of Sales
James R. Sulat - Director
Punit Dhillon - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 03939W109
SIC: 3841
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/19/22
Share - Related Items
Shares Outstanding: 237.07
Most Recent Split Date: (:1)
Beta: -0.51
Market Capitalization: $18.97 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.01 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.03 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/19/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 155.59%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -146.90
09/30/21 - -141.62
Current Ratio
03/31/22 - -
12/31/21 - 1.30
09/30/21 - 2.12
Quick Ratio
03/31/22 - -
12/31/21 - 0.74
09/30/21 - 1.49
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -42,634.11
09/30/21 - -53,955.90
Book Value
03/31/22 - -
12/31/21 - -0.01
09/30/21 - 0.00
Inventory Turnover
03/31/22 - -
12/31/21 - 0.04
09/30/21 - 0.03
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©